^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    DSC1 (Desmocollin 1)

    i
    Other names: DSC1, Desmocollin 1, CDHF1, Desmosomal Glycoprotein 2/3, Cadherin Family Member 1, Desmocollin-1, DG2/DG3
    Associations

    News

    Trials
    8ms
    Loss of cadherin 17 downregulates LGR5 expression, stem cell properties and drug resistance in metastatic colorectal cancer cells. (PubMed, Cell Death Dis)
    Consequently, the loss of CDH17 increased sensitivity to 5-FU, irinotecan, oxidative stress and anoikis in CRC cells...In conclusion, CDH17 plays a crucial role in maintaining colorectal cancer cell stemness and chemoresistance via LGR5/Wnt/MYC signaling and SLC38A5 expression. These findings underscore the therapeutic potential of CDH17 targeting in metastatic CRC, and support the use of amiloride for inhibiting liver metastasis.
    Journal
    |
    CDH17 (Cadherin 17) • DSC1 (Desmocollin 1) • LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5)
    |
    5-fluorouracil • irinotecan
    9ms
    Discovery of new protein partners of anterior gradient 2 (AGR2) from cell-cell adhesion pathway using genetically-encoded photo-crosslinker DiZPK. (PubMed, Bioorg Med Chem)
    Further protein-protein interaction studies, including immunofluorescence and molecular dynamic simulation analysis, especially using γ-catenin as an example, corroborated with the observation that AGR2 directly interacts with γ-catenin. We believe the identification of these new protein partners would help to unveil how AGR2 renders its roles in cell adhesion, migration, and ultimately metastasis of cancers, and these proteins are worthy of future in-depth study for the elucidation of AGR2-mediated cellular functions.
    Journal
    |
    AGR2 (Anterior gradient 2) • DSC1 (Desmocollin 1)
    2years
    A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration and invasion according to the cell phenotype. (PubMed, J Exp Clin Cancer Res)
    These findings shed light on the multifaceted roles of CDH17, DSC1, and p120-catenin in CRC metastasis, offering insights into potential therapeutic interventions for targeting desmosomal cadherins in poorly-differentiated carcinomas.
    Journal
    |
    CTNND1 (Catenin Delta 1) • CDH17 (Cadherin 17) • DSC1 (Desmocollin 1)
    |
    CDH1 expression
    over2years
    A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer. (PubMed, Heliyon)
    Contrary to the usual normal bladder tissue to blood ratio, DLX1 expression was lower (p = 0.02734) in tumor tissues than in blood. Being the first research of p53 pathway related signature gene set in bladder cancer, this study potentially has a substantial impact on the development of biomarkers for BLCA.
    Journal • Gene Signature
    |
    DLX1 (Distal-Less Homeobox 1) • DSC1 (Desmocollin 1)
    over2years
    Canine Somatic Mutations from Whole-Exome Sequencing of B-Cell Lymphomas in Six Canine Breeds-A Preliminary Study. (PubMed, Animals (Basel))
    Through a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of 17 genes with somatic mutations, a total of 16 pathways were identified. Overall, the somatic mutations identified in this study suggest novel candidate mutations for CL, and further studies are needed to confirm the role of these mutations.
    Journal
    |
    DSC1 (Desmocollin 1) • SEMA6B (Semaphorin 6B) • ADORA2B (Adenosine A2b Receptor) • ITM2B (Integral Membrane Protein 2B)
    over2years
    Desmocollin-1 is associated with pro-metastatic phenotype of luminal A breast cancer cells and is modulated by parthenolide. (PubMed, Cell Mol Biol Lett)
    Our systems biology data indicate that DSC1 is connected to mechanisms of cell cycle regulation in luminal A breast cancer cells, and can be effectively modulated by parthenolide.
    Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CDH1 (Cadherin 1) • CDK2 (Cyclin-dependent kinase 2) • CDH3 (Cadherin 3) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5) • DSC1 (Desmocollin 1) • MCM2 (Minichromosome maintenance complex component 2) • DSG2 (Desmoglein 2)
    almost3years
    A novel circadian cycle-related gene signature for prognosis prediction of patients with breast cancer. (PubMed, Medicine (Baltimore))
    Furthermore, patients of different risk levels exhibit varying degrees of sensitivity to vinorelbine, lapatinib, metformin, and vinblastine. Our study indicated the disruption of the expression of CCRGs in BC and built a favorable prognostic risk model based on 3 independent prognostic CCRGs. These genes may be applied as candidate molecular targets for the diagnosis and therapy of BC.
    Journal • Gene Signature
    |
    CDH23 (Cadherin Related 23) • DSC1 (Desmocollin 1)
    |
    lapatinib • vinorelbine tartrate • metformin • vinblastine
    almost3years
    Investigating the role of Desmocollin-3 and immune infiltrate in bladder cancer (AACR 2023)
    DSC3 expression is associated with the Basal/Squamous type of bladder cancer. Therefore, this study suggests the potential of DSC3 as a predictive biomarker for response to systemic immunotherapy and resistance/poor response to conventional therapy (chemotherapy; radiotherapy, and cystectomy) and underscores the need for studies evaluating the potential of DSC3 expression as a biomarker.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • DSC1 (Desmocollin 1)
    |
    PD-L1 expression
    3years
    Next-Generation Sequencing (NGS) of Multivergent Morphologies in Colorectal Carcinomas (CRCs) Identifies Unique Targetable Alterations (USCAP 2023)
    Multivergent morphology is rare in CRC but is highly predictive of the presence of targetable molecular alterations. In such cases, NGS of multiple areas with different morphology may identify potential therapeutic targets that would otherwise be missed. While most cases have recognizable driver alterations, the less common targetable alterations frequently identified in these cases could open up additional trial options for salvage therapy.
    Tumor mutational burden • MSi-H Biomarker • BRCA Biomarker • IO biomarker • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • DNMT3A (DNA methyltransferase 1) • ARID1A (AT-rich interaction domain 1A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • POLE (DNA Polymerase Epsilon) • GNAQ (G Protein Subunit Alpha Q) • RUNX1 (RUNX Family Transcription Factor 1) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • PALB2 (Partner and localizer of BRCA2) • KMT2A (Lysine Methyltransferase 2A) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • TOP2A (DNA topoisomerase 2-alpha) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • KMT2D (Lysine Methyltransferase 2D) • PTCH1 (Patched 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • RNF43 (Ring Finger Protein 43) • CDK12 (Cyclin dependent kinase 12) • SMAD4 (SMAD family member 4) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • KMT2C (Lysine Methyltransferase 2C) • PMS2 (PMS1 protein homolog 2) • WT1 (WT1 Transcription Factor) • ATRX (ATRX Chromatin Remodeler) • B2M (Beta-2-microglobulin) • CDH1 (Cadherin 1) • CHEK2 (Checkpoint kinase 2) • CREBBP (CREB binding protein) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • BCOR (BCL6 Corepressor) • FAT1 (FAT atypical cadherin 1) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • RBM10 (RNA Binding Motif Protein 10) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • GLI1 (GLI Family Zinc Finger 1) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • STAG2 (Stromal Antigen 2) • CUL4A (Cullin 4A) • EP300 (E1A binding protein p300) • IL7R (Interleukin 7 Receptor) • RAD51D (RAD51 paralog D) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • SETBP1 (SET Binding Protein 1) • ARID2 (AT-Rich Interaction Domain 2) • MSH3 (MutS Homolog 3) • NOTCH4 (Notch 4) • GNAS (GNAS Complex Locus) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • NCOR1 (Nuclear Receptor Corepressor 1) • PIM1 (Pim-1 Proto-Oncogene) • CASP8 (Caspase 8) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • DICER1 (Dicer 1 Ribonuclease III) • FANCM (FA Complementation Group M) • KMT2B (Lysine Methyltransferase 2B) • POT1 (Protection of telomeres 1) • PRDM1 (PR/SET Domain 1) • AMER1 (APC Membrane Recruitment Protein 1) • CHD4 (Chromodomain Helicase DNA Binding Protein 4) • CSMD3 (CUB And Sushi Multiple Domains 3) • FANCD2 (FA Complementation Group D2) • LATS1 (Large Tumor Suppressor Kinase 1) • TAP1 (Transporter 1) • ACVR2A (Activin A Receptor Type 2A) • CUL4B (Cullin 4B) • DSC1 (Desmocollin 1) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • RASA1 (RAS P21 Protein Activator 1) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit) • USP9X (Ubiquitin Specific Peptidase 9 X-Linked)
    |
    TMB-H • MSI-H/dMMR • POLE mutation • RNF43 mutation • PMS2 mutation
    |
    Oncomine™ Comprehensive Assay Plus
    over3years
    Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling. (PubMed, NPJ Precis Oncol)
    Mutations in RTK genes, MAPK pathway genes, and PI3K/AKT pathway genes likely represent key mutations in SDC tumorigenesis. The gene expression profiles identified in this study may be useful for stratifying patients who are good candidates for CAB treatment and may benefit from additional systemic therapies.
    Journal
    |
    IGLL5 (Immunoglobulin Lambda Like Polypeptide 5) • DSC1 (Desmocollin 1)
    over3years
    Subcorneal pustular dermatosis-type IgA pemphigus associated with multiple myeloma: A case report and literature review. (PubMed, J Dermatol)
    Daratumumab, lenalidomide, and dexamethasone (DLd) therapy was effective for both the MM and the skin lesions, resulting in negative results on Dsg1/3 and Dsc1-3 IgA ELISAs. Literature review revealed associations between SPD-type and IgA κ chain in IgA pemphigus and MM, and that in most cases the onset or diagnosis of MM was simultaneous or occurred after the diagnosis of IgA pemphigus. Therefore, clinicians should be aware of the development of multiple myeloma during the clinical course of patients with SPD-type IgA pemphigus.
    Review • Journal
    |
    DSC1 (Desmocollin 1)
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone